文献速递自身免疫性与大疱性皮肤病

JAK/STAT信号通路参与大疱性类天疱疮免疫机制

Janus kinase/signal transducer and activator of transcription signalling pathway is involved in the immune mechanism of bullous pemphigoid.
PubMed 文献 · Br J Dermatol · 2025-01-01

该研究通过皮肤转录组、血浆细胞因子检测及体外T细胞活化与JAK抑制剂阻断实验,分析大疱性类天疱疮(BP)患者的免疫特征及JAK/STAT通路作用,并评估JAK抑制剂对激素抵抗BP的临床疗效。

要点

  • BP患者皮损中JAK3和STAT3 mRNA水平升高。
  • BP相关炎症因子/趋化因子(IL-5、CCL22等)显著升高(均P<0.001)。
  • 托法替尼和利特昔替尼体外抑制颗粒酶B和CCL17效果优于乌帕替尼。

核心结论

  • JAK3抑制剂可减弱JAK3/STAT3介导的炎症因子,与低剂量激素联用为难治性BP提供替代治疗策略。

研究设计与样本

  • 评估8例激素抵抗BP患者口服托法替尼的临床改善。

主要发现

  • BP患者皮损中JAK3和STAT3 mRNA水平升高。
  • BP相关炎症介质包括IL-5、CCL22、CCL17、CCL18、MMP9和颗粒酶B在BP患者中显著高于健康供者(均P<0.001)。
  • 体外实验显示托法替尼(JAK1/3i)和利特昔替尼(JAK3i)对BP患者颗粒酶B和CCL17的抑制效果优于乌帕替尼。
  • 8例激素抵抗BP患者口服托法替尼后,5例在5周内BPDAI从104.2快速降至34.8。

关键数值与推荐

  • BP患者皮损JAK3和STAT3 mRNA水平升高。
  • BP相关炎症介质(IL-5、CCL22、CCL17、CCL18、MMP9、颗粒酶B)在BP患者中显著升高(均P<0.001)。
  • 托法替尼和利特昔替尼体外抑制颗粒酶B和CCL17效果优于乌帕替尼。
  • 8例激素抵抗BP患者口服托法替尼,5例5周内BPDAI从104.2降至34.8。

临床怎么用

  • JAK3抑制剂联合低剂量激素可考虑用于难治性BP患者。
  • 托法替尼可能快速改善激素抵抗BP的疾病活动度。

局限性

  • JAK抑制剂临床评估仅8例激素抵抗BP患者,样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bullous pemphigoid (BP) is a common immunobullous disease that mainly affects older people; however, the molecular pathogenesis of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway in BP is not fully understood. OBJECTIVES: To characterize the immune profiles of and the key JAK/STAT pathway in patients with BP. The clinical efficacy of JAK inhibition in patients with BP was also assessed. METHODS: Skin transcriptome profiling, measurement of plasma cytokine/chemokine levels, and an in vitro T-cell activation and JAK inhibitor (JAKi) blocking assay were performed for patients with BP. The clinical improvement in steroid-resistant patients with BP treated with JAKi was evaluated. RESULTS: Fifty patients with BP and 31 healthy donor individuals were enrolled in this study. JAK3 and STAT3 mRNA levels were increased in skin lesions from patients with BP. BP-related inflammatory-mediated cytokines/chemokines, including interleukin 5, CCL22, CCL17, CCL18, matrix metalloproteinase 9 and granzyme B, were significantly elevated in patients with BP compared with the healthy donors (all P < 0.001). An in vitro T-cell activation and JAKi blocking assay revealed that tofacitinib (JAK1/3i) and ritlecitinib (JAK3i) had better inhibitory effects than upadacitinib on granzyme B and CCL17 in patients with BP. Eight patients with steroid-resistant BP were treated with oral tofacitinib. Of these patients, five had a rapid reduction in their Bullous Pemphigoid Disease Area Index (from 104.2 to 34.8) within 5 weeks. CONCLUSIONS: JAK3i can attenuate JAK3/STAT3-mediated inflammatory factors, providing an alternative treatment strategy for patients with refractory BP in combination with low-dose steroids. Bullous pemphigoid (or ‘BP’ for short) is a common disease that mainly affects older people. In Asia, approximately 1 individual in 100 has BP. How BP develops at a molecular level is still unknown. It may involve a cellular pathway called the ‘JAK/STAT’ pathway. In this study, we aimed to find out immune profiles and the key JAK/STAT pathway in patients with BP. The effectiveness of medications called ‘JAK inhibitors’ in patients with BP was also investigated. We analysed a variety of things in patients with BP. This included which genes were active in their skin and the levels of certain proteins in their blood. We also carried out laboratory testing to find out how JAK inhibitors work in patients BP. Improvements in patients with difficult-to-treat BP taking JAK inhibitors were evaluated. Fifty people with BP and 31 people without the disease took part. The expression of genes called ‘JAK3’ and ‘STAT3’ were much higher in skin lesions from patients with BP. We found that factors involved in the JAK3/STAT3 signalling pathway were activated. Certain inflammation-related proteins associated with BP were higher in patients with BP. In lab tests, we found that drugs called tofacitinib and ritlecitinib were better at blocking two of these proteins in BP. Eight patients with steroid-resistant BP took tofacitinib. Five of these patients had a rapid improvement in their disease within 5 weeks. Our findings suggest that JAK3 inhibitors can reduce the levels of inflammation-related factors in BP. When combined with low-dose steroids, JAK inhibitors are an option for patients with difficult-to-treat BP.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Chung HY, Chen CB, Lee HE, et al. Janus kinase/signal transducer and activator of transcription signalling pathway is involved in the immune mechanism of bullous pemphigoid. Br J Dermatol. 2025. PMID: 40577521. doi:10.1093/bjd/ljaf219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。